A co-formulated vial holding two or three different peptides is the most expensive thing in most research-peptide catalogues, and the hardest to verify. A single purity percentage on a single-peptide vial is already a narrower claim than most buyers assume. On a vial holding three peptides, the same number can be close to uninformative — not because anyone is being dishonest, but because of what area-percent chromatography actually measures.
This article sets out what a certificate for a multi-peptide vial can establish, what it cannot, and which additional measurements close the gap. The standards it draws on were written for pharmaceutical manufacturing rather than for research reagents, and we say so each time, because borrowing a benchmark is useful and claiming to be bound by one would not be true.
The short answer
- Area-percent purity is a relative measure. It tells you what share of the detected signal is a given peak, not what share of the vial’s mass is a given peptide.
- Equal mass does not give equal peak area. UV absorptivity at 214 nm depends on amino-acid composition: tryptophan absorbs roughly thirty times as strongly as a peptide bond.
- ICH’s own validation guideline anticipates this. Q2(R2) requires a correction factor when a relative response factor falls outside 0.8 to 1.2.
- One peak is not one compound. Two peptides can co-elute, and isomers produce identical mass data, so neither chromatography nor mass spectrometry alone is sufficient.
- Selectivity, not specificity, is the governing concept for a mixture — and ICH says that where one procedure cannot discriminate, two or more should be used.
- Quantitation needs a reference standard per component, because ionisation efficiency is peptide-specific.
- Each component brings its own counter-ion and water, so labelled total mass is not the sum of the peptide masses.
- No pharmacopoeial standard covers multi-peptide blends. We could find none in USP, ICH or the regulator guidance we reviewed.
Co-formulated multi-peptide vials
“blends” in trade usage · two or more distinct peptides in one container
- What area percent measures
- The share of detected signal under one peak, relative to total detected signal
- Why that is not mass
- Molar extinction at 214 nm varies with composition; the peptide bond itself is 923 M−1 cm−1
- ICH response-factor rule
- Q2(R2) Annex 2: a correction factor applies when the relative response factor is outside 0.8 to 1.2
- Governing validation concept
- Selectivity — the extent to which analytes in mixtures can be measured — rather than specificity
- What resolves components
- Orthogonal separation plus mass detection, with a reference standard for each component
- Counter-ions
- USP has separate chapters for acetic acid and for TFA in peptides; each is a measurable mass fraction
- Dedicated blend standard
- None located in USP, ICH or the regulator guidance reviewed
Where the standards reach
- Single synthetic peptide drug substances
- Analytical validation principles
- Counter-ion and water content methods
- Co-formulated multi-peptide products
The analytical principles are well established. A standard written specifically for multi-peptide vials is the gap, and it is why documentation practice varies so widely.
Why a purity number is relative
Reverse-phase HPLC with UV detection separates a sample into peaks and integrates the area under each one. Area percent expresses one peak’s area as a fraction of the total integrated area. That is a relative statement about detected material, and two consequences follow that matter more for mixtures than for single compounds.
The first is that anything the detector does not see does not enter the denominator. Counter-ions, water and inorganic residues are not chromophores at 214 nm in the way a peptide backbone is, so they are largely invisible to the calculation. A vial can be 99 per cent pure by area and still be a minority peptide by mass. Our article on net peptide content and counter-ions works through that arithmetic for single peptides.
The second is specific to co-formulation. On a single-peptide certificate, area percent at least answers a coherent question: how much of what we detected is the compound we wanted. On a three-peptide vial, “purity” has to be defined before it means anything. Purity of which component? Against which denominator? A number reported without that definition is not wrong so much as unanswerable.
Equal mass, unequal peak
Here is the part that surprises people, and it is measurable rather than theoretical. Peptides do not absorb ultraviolet light in proportion to their mass. Detection at 214 nm picks up the peptide bond itself, but several side chains absorb far more strongly.
A 2007 study in the Journal of Agricultural and Food Chemistry by Kuipers and Gruppen measured molar extinction coefficients for peptides at 214 nm in the presence of acetonitrile and formic acid, in order to make quantitative comparison possible. It reports that “the peptide bond has a molar extinction coefficient of 923 M−1 cm−1”, and that tryptophan absorbs roughly thirty times that; phenylalanine, tyrosine and histidine around six times; methionine about the same as a peptide bond; and proline negligibly on its own but around three times a peptide bond when it sits within a chain. It is a food-chemistry paper on protein hydrolysates rather than a peptide quality-control paper, and we describe it that way — but the physics it measures applies to any peptide in a UV detector.
So two peptides present in identical amounts can produce markedly different peak areas, purely because one is tryptophan-rich and the other is not. In a co-formulated vial that means the ratio of peak areas is not the ratio of the components unless someone has corrected for each component’s response.
The regulator anticipates exactly this. ICH Q2(R2), the current guideline on validating analytical procedures, states in Annex 2 that “if the relative response factor is outside the range 0.8-1.2, then a correction factor should be applied.” That is a pharmaceutical-manufacturing guideline and a research reagent is not subject to it. But it tells you the professional standard treats uncorrected area percent as inadequate once response factors diverge — which, given a thirty-fold spread in side-chain absorptivity, they readily can.
One peak is not one compound
A clean chromatogram is reassuring and it is not proof. Two different peptides can emerge from the column at the same retention time under a given gradient, and when they do, the trace shows one peak with no visual hint that anything is hiding underneath it.
A 2026 practitioner article in LCGC International on two-dimensional liquid chromatography for GLP-1 analysis describes precisely this: a one-dimensional reverse-phase separation that gave “no visual indication of coeluting species”, and a second, orthogonal separation that revealed “additional impurities hiding underneath”. It is a vendor-partnered piece rather than peer-reviewed work, so we pair it with the regulator position below. Its most useful observation is that the obvious fix is not sufficient either: “mass spectrometry alone can be misleading here, since isomers produce identical MS data to the parent peak”, and “only an orthogonal chromatographic separation can resolve them”.
That cuts both ways, and it is worth holding onto. Chromatography alone cannot prove one peak is one compound. Mass spectrometry alone cannot distinguish isomers. The honest answer is that neither technique is sufficient by itself, which is also what the validation guidance says. Our comparison of HPLC and UPLC covers how method choices change what a chromatogram shows.
Selectivity is the right concept
The validation vocabulary here is worth getting right, because the two words people use interchangeably mean different things in the guideline.
ICH Q2(R2) distinguishes them: “specificity is typically used to describe the ultimate state, measuring unequivocally a desired analyte”, while selectivity is the relative term, describing “the extent to which particular analytes in mixtures or matrices can be measured”. A multi-peptide vial is a mixture, so selectivity is the governing concept, and the guideline is explicit that a procedure can be selective without being specific.
What the guideline then says is the useful part: “where one analytical procedure does not provide sufficient discrimination, a combination of two or more procedures is recommended to achieve the necessary specificity/selectivity”, and “in case a single procedure is not considered specific or sufficiently selective, an additional procedure should be used”. A newly issued Saudi FDA guidance on synthetic peptide quality takes the same line for identity, requiring that at least two orthogonal methods be employed. Our article on analytical method validation covers the wider parameter set.
Quantitation needs a standard per component
If area percent will not give you the component ratio, the obvious alternative is mass spectrometry. That works for identity and it does not, on its own, work for quantity, because ionisation efficiency is peptide-specific.
A 2015 paper in Nature Communications by Curran and colleagues, developing a multiplexed absolute-quantification method, reports that “for a given concentration the response ratio can vary by two to three orders of magnitude”, attributing it to differences in ionisation potential between peptides and their co-eluting species, and notes that “the calibration curve is unique to each phosphorylated peptide due to different response profiles”. That spread was measured on phosphopeptides against a complex biological background rather than on research-peptide vials, so we are citing the mechanism rather than transferring the figure. The mechanism is the transferable part: MS peak intensity is not proportional to mass across different peptides.
Which is why a reference standard per component is the answer, and why regulator guidance says so independently. The Saudi FDA synthetic-peptide guidance states that “the method should include a reference standard”. For a three-peptide vial, that means three standards and three calibrations, not one.
Counter-ions, water and the labelled mass
Synthetic peptides arrive as salts. Each component in a co-formulated vial carries its own counter-ion burden and its own residual water, which is why the labelled total mass is not the sum of the peptide masses.
That this is a real, measurable mass fraction rather than a rounding concern is clear from the fact that the pharmacopoeia devotes separate general chapters to it: USP has a chapter on acetic acid in peptides and another on trifluoroacetic acid in peptides, with a sodium trifluoroacetate reference standard. The Saudi FDA guidance treats peptide content and water content as distinct specification tests, states that “assay of the synthetic peptide product can be presented on an anhydrous or counter-ion-free basis”, and notes that “identification of counter-ion is important due to its effect in the secondary structure of peptides”.
The practical reading: a certificate for a co-formulated vial that reports one purity figure and a total mass has not told you how much of any component is present. Peptide content, water content and counter-ion identity are separate questions with separate methods.
What the standards actually cover
We went looking for a pharmacopoeial or regulatory standard written for multi-peptide blends and could not find one. Here is what exists, and where each one stops.
| Standard | What it covers | Where it stops |
|---|---|---|
| ICH Q7, section 8.4 | Blending batches of material “within the same specification” to produce a homogeneous intermediate or active ingredient | It is batch-to-batch blending of the same substance, not co-formulation of different peptides. It is also GMP for medicinal active ingredients, so a research reagent is outside its scope |
| ICH Q2(R2) | Validation principles: selectivity, response factors, when to combine procedures | Principles, not a product standard, and again written for pharmaceutical procedures |
| USP chapters on synthetic peptides | Quality attributes of synthetic peptide drug substances, in the singular; starting materials; acetic acid and TFA content | No chapter we located addresses two or more different peptides co-formulated in one container |
| Saudi FDA synthetic peptide guidance | Specification tests, orthogonal identity methods, counter-ion and water | Its scope excludes co-formulated multi-peptide products, and it takes effect on 29 October 2026 |
| ISO/IEC 17025:2017 | What an accredited testing laboratory must put in its report | It binds the laboratory, not the supplier. A vendor-authored certificate is not an accredited laboratory report |
Two of those rows are worth dwelling on. ICH Q7’s blending section is often cited in this context, and it does contain a useful benchmark: section 8.44 states that “the batch record of the blending process should allow traceability back to the individual batches that make up the blend”, and section 8.41 that “out-of-specification batches should not be blended with other batches for the purpose of meeting specifications”. We cite those as the standard the pharmaceutical industry sets for itself, not as a rule binding a research-reagent vendor, because Q7 defines blending as combining materials of the same specification and governs active ingredients for medicinal use. Our article on lot numbers and batch traceability develops the traceability point.
The ISO row carries the most useful consumer-facing lesson. Clause 7.8.2.1 l) of ISO/IEC 17025:2017 requires a test report to carry a statement to the effect that the results relate only to the items tested — we are paraphrasing, because the standard’s text is not free to reproduce. The European co-operation for Accreditation holds that this statement is needed in all test reports and cannot be waived by agreement with the customer. The point for a buyer is simple: a report speaks only to the material that was sampled, which is why batch matching is not a formality.
What’s established and what isn’t
Reasonably well established
- Area-percent HPLC purity is a relative measure of detected material, not a mass fraction of the vial.
- Molar extinction at 214 nm varies with amino-acid composition; the peptide bond is 923 M−1 cm−1 and tryptophan absorbs roughly thirty times as strongly.
- ICH Q2(R2) requires a correction factor when a relative response factor falls outside 0.8 to 1.2.
- Two peptides can co-elute, and isomers give identical mass spectra, so neither technique alone is sufficient.
- Ionisation efficiency is peptide-specific, so quantitation by mass spectrometry requires a reference standard per component.
- Counter-ion and water content are separate, measurable specification tests with their own pharmacopoeial chapters.
Open questions
- What a defensible specification for a multi-peptide research vial should contain. No pharmacopoeial or regulatory standard we located addresses it.
- How large the response-factor spread is for the specific peptide pairs in common co-formulations. We found no published measurement.
- Whether co-formulation affects the stability of either component. ICH Q7 requires stability testing where blending could affect it, but that is a pharmaceutical requirement, not a published finding about these mixtures.
- How widely orthogonal identity confirmation is actually applied to research-grade blends, as opposed to recommended.
What to ask for
If you are buying a co-formulated vial for laboratory work, these are the questions that actually discriminate between documentation that means something and documentation that does not.
- Is each component identified by mass, separately? Identity per component is the first thing a blend certificate should establish. Our mass spectrum guide covers reading the result.
- Is “purity” defined? Which component, against which denominator. An undefined percentage on a mixture is not an answerable claim.
- Was more than one separation or detection mode used? ICH’s own position is that one procedure is often not enough for a mixture.
- Are peptide content and water reported separately from purity? They are different measurements with different methods.
- Does the batch number on the report match the vial in your hand? Our COA guide covers the rest of what a useful certificate contains.
Co-formulated vials with published test reports
These are the multi-peptide products in our catalogue. Janoshik test reports are listed by batch on our Lab Testing page.
Coremend BlendThree components: TB-500, KPV and BPC-157View product
GHK-Cu + KPV BlendTwo tripeptides co-formulatedView product
BPC-157 + TB-500 BlendTwo components of very different massView product
CJC-1295 + IpamorelinA co-formulated vial we cover in depth separatelyView product
Research use only. Pure Peptides Canada products are laboratory reagents for in-vitro research, not for human or veterinary use. This article explains published research for education; it is not medical, dietary or dosing guidance.
Frequently asked questions
Why is a purity figure less useful on a peptide blend?
Because area-percent purity is a relative measure. It expresses one chromatographic peak’s area as a share of the total detected area, which on a single-peptide vial answers a coherent question. On a vial holding three different peptides, the figure has to be defined before it means anything: purity of which component, measured against which denominator. A percentage reported without that definition is not so much wrong as unanswerable.
Does a bigger peak mean more of that peptide?
Not reliably. Peptides do not absorb ultraviolet light in proportion to their mass. Measured molar extinction coefficients at 214 nanometres show the peptide bond at 923 per molar per centimetre, with tryptophan absorbing roughly thirty times as strongly and phenylalanine, tyrosine and histidine around six times. So a tryptophan-rich peptide produces a much larger peak than an equal amount of a peptide without aromatic residues. Comparing components by peak area requires correcting for each one’s response factor.
Can mass spectrometry alone verify a blend?
It is necessary but not sufficient. Mass detection identifies each component by its distinct mass, which chromatography alone cannot do. But isomers produce identical mass data, so a mass measurement cannot distinguish a peptide from a same-formula rearrangement, and ionisation efficiency varies between peptides by a wide margin, so peak intensity is not proportional to amount. ICH’s validation guidance says that where one procedure does not discriminate sufficiently, two or more should be combined.
Is there a standard for testing multi-peptide blends?
We could find none. The USP chapters on synthetic peptides address drug substances in the singular and the starting materials for their synthesis. ICH Q2(R2) gives validation principles rather than a product standard. ICH Q7’s blending section concerns combining batches of the same material, not co-formulating different peptides. A recently issued Saudi FDA guidance on synthetic peptide quality explicitly excludes co-formulated multi-peptide products from its scope. That absence is why documentation practice for these products varies so much between suppliers.
Does ICH Q7 apply to a research peptide blend?
No. Q7 is Good Manufacturing Practice guidance for active pharmaceutical ingredients destined for medicinal products, and it defines blending as combining materials within the same specification to make a homogeneous intermediate or active ingredient. Neither the scope nor the definition fits a research-use-only vial holding two different peptides. We cite its traceability requirement as a benchmark the pharmaceutical industry sets for itself, which is a useful reference point, not as a rule a research-reagent supplier is bound by.
What does the ISO 17025 statement about tested items mean for me?
Clause 7.8.2.1 l) of ISO/IEC 17025:2017 requires an accredited laboratory’s test report to carry a statement to the effect that the results relate only to the items tested. The European co-operation for Accreditation holds that this cannot be omitted and cannot be waived by agreement with the customer. For a buyer the practical consequence is that a certificate describes the specific material that was sampled and nothing else, which is why matching the batch number on the report to the vial in your hand is the step that gives the document meaning. Note also that the clause binds the testing laboratory, not a vendor writing its own certificate.
Why does the labelled mass not equal the peptide mass?
Because synthetic peptides are supplied as salts, and in a co-formulated vial every component brings its own counter-ion and its own residual water. That burden is a real, measurable mass fraction rather than a rounding issue, which is why the pharmacopoeia has separate general chapters for acetic acid and for trifluoroacetic acid in peptides. Regulator guidance treats peptide content and water content as distinct specification tests and allows an assay to be reported on an anhydrous or counter-ion-free basis, which is a different number from the labelled total.
Co-formulated vials, documented by batch
The multi-peptide range, priced in Canadian dollars and shipped tracked from inside Canada.
References
- International Council for Harmonisation. ICH Q7, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Sections 8.40 to 8.47 on blending; glossary. Guideline
- International Council for Harmonisation. ICH Q2(R2), Validation of Analytical Procedures. Section 3.1.1 and 3.1.2.2 on specificity and selectivity; Annex 2 on relative response factors; glossary. Guideline
- Kuipers BJH, Gruppen H. Prediction of molar extinction coefficients of proteins and peptides using UV absorption of the constituent amino acids at 214 nm to enable quantitative reverse phase high-performance liquid chromatography-mass spectrometry analysis. J Agric Food Chem. 2007;55(14):5445–5451. Abstract and metadata consulted. DOI
- Curran TG, Zhang Y, Ma DJ, Sarkaria JN, White FM. MARQUIS: a multiplex method for absolute quantification of peptides and posttranslational modifications. Nat Commun. 2015;6:5924. DOI
- Whitmarsh S, Sharma N, Alvarez P. 2D-LC and orthogonal separation in practice for GLP-1 analysis. LCGC International, 7 October 2026. Practitioner article, vendor-partnered, not peer-reviewed.
- Saudi Food and Drug Authority. Quality Requirements for Synthetic Peptides, DS-G-143-V01. Issued 29 September 2026; effective 29 October 2026. Guidance
- United States Pharmacopeia. General chapters on synthetic peptides, including quality attributes of synthetic peptide drug substances, acetic acid in peptides and trifluoroacetic acid in peptides. Chapter titles consulted; full texts are subscriber-only.
- International Organization for Standardization. ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories, clause 7.8.2.1 l). Clause located and substance confirmed via the European co-operation for Accreditation FAQ 42-1 and the NIST reporting crosswalk; ISO text not reproduced. Standard
For laboratory research use only. Not for human or veterinary use. This article summarizes published research for educational purposes and is not medical advice.
